Key Points
- Embecta CFO Jacob Elguicze bought 20,000 shares at an average price of $4.67, increasing his stake by 6.92% to 309,139 shares. Company executives and a director collectively purchased 70,000 shares, potentially signaling confidence in the stock’s valuation.
- Embecta reported quarterly EPS of $0.56, well above the $0.27 consensus estimate, while revenue of $271.7 million also exceeded expectations. However, revenue fell 8.1% year over year, and the stock remains near its 52-week low.
- Investor concerns remain significant: analysts have an average “Reduce” rating, Bank of America cut its price target to $3, and a securities class-action lawsuit alleges misleading statements about the insulin pen-needle business and fiscal 2026 guidance.
Embecta Corp. (NASDAQ:EMBC - Get Free Report) CFO Jacob Elguicze acquired 20,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 12th. The stock was bought at an average price of $4.67 per share, for a total transaction of $93,400.00. Following the completion of the transaction, the chief financial officer owned 309,139 shares of the company's stock, valued at $1,443,679.13. The trade was a 6.92% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link.
Embecta Stock Performance
Embecta stock opened at $5.11 on Friday. Embecta Corp. has a fifty-two week low of $2.77 and a fifty-two week high of $15.55. The stock has a market cap of $289.53 million, a P/E ratio of 3.45 and a beta of 0.81. The firm's fifty day moving average price is $3.46 and its 200-day moving average price is $6.42.
Embecta (NASDAQ:EMBC - Get Free Report) last released its earnings results on Friday, August 7th. The company reported $0.56 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.29. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The business had revenue of $271.70 million for the quarter, compared to analysts' expectations of $254.53 million. During the same quarter in the prior year, the firm earned $1.12 earnings per share. The firm's revenue was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. On average, analysts predict that Embecta Corp. will post 1.84 earnings per share for the current year.
Embecta Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 15th. Stockholders of record on Thursday, August 27th will be given a dividend of $0.01 per share. The ex-dividend date is Thursday, August 27th. This represents a $0.04 annualized dividend and a dividend yield of 0.8%. Embecta's dividend payout ratio is 2.70%.
Embecta News Roundup
Here are the key news stories impacting Embecta this week:
- Positive Sentiment: CEO Devdatt Kurdikar, CFO Jacob Elguicze and director Jeffrey Z. Mann collectively bought 70,000 Embecta shares worth approximately $334,200 on August 12. The purchases increased their individual holdings and may signal management confidence that the stock is undervalued. SEC insider transaction filing
- Neutral Sentiment: Several investor-rights firms are reminding shareholders that August 17, 2026, is the deadline to seek appointment as lead plaintiff for investors who purchased EMBC shares between November 25, 2025, and May 4, 2026. These announcements largely repeat the same lawsuit information rather than represent new company operating news. BFA Law class action reminder
- Negative Sentiment: The filed class action alleges that Embecta and certain executives violated federal securities laws by misrepresenting the commercial stability of its insulin pen-needle business and issuing misleading fiscal 2026 guidance. The claims follow a significant stock decline and could create legal costs, reputational damage and additional uncertainty around management credibility. The allegations have not been proven in court. Hagens Berman lawsuit alert
Wall Street Analyst Weigh In
A number of research analysts have commented on EMBC shares. Zacks Research upgraded shares of Embecta from a "strong sell" rating to a "hold" rating in a research report on Friday, July 17th. BTIG Research lowered shares of Embecta from a "buy" rating to a "neutral" rating in a report on Tuesday, May 5th. Weiss Ratings downgraded shares of Embecta from a "sell (d+)" rating to a "sell (d)" rating in a research note on Monday, August 3rd. Wall Street Zen cut Embecta from a "strong-buy" rating to a "hold" rating in a research note on Saturday, May 9th. Finally, Bank of America decreased their price objective on Embecta from $11.00 to $3.00 and set an "underperform" rating on the stock in a report on Monday, May 18th. Three investment analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Reduce" and an average price target of $11.00.
View Our Latest Analysis on Embecta
Hedge Funds Weigh In On Embecta
Hedge funds have recently modified their holdings of the company. Walleye Capital LLC bought a new position in Embecta during the 1st quarter valued at approximately $7,013,000. SG Americas Securities LLC lifted its position in shares of Embecta by 138.4% in the 1st quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company's stock worth $9,184,000 after purchasing an additional 603,106 shares during the period. Ameriprise Financial Inc. increased its position in shares of Embecta by 439.1% during the second quarter. Ameriprise Financial Inc. now owns 709,849 shares of the company's stock valued at $6,878,000 after buying an additional 578,174 shares during the period. Jefferies Financial Group Inc. raised its stake in Embecta by 24.9% in the fourth quarter. Jefferies Financial Group Inc. now owns 2,354,971 shares of the company's stock worth $27,977,000 after buying an additional 470,096 shares in the last quarter. Finally, UBS Group AG lifted its holdings in Embecta by 200.8% in the fourth quarter. UBS Group AG now owns 630,994 shares of the company's stock worth $7,496,000 after buying an additional 421,254 shares during the period. Hedge funds and other institutional investors own 93.83% of the company's stock.
About Embecta
(
Get Free Report)
Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.
The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
